A Phase 1 interventional study of Biopsy Procedure and Biospecimen Collection in Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm and Refractory Malignant Solid Neoplasm, sponsored by National Cancer Institute (NCI). Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment
How we know · 8 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis — 10 open to participants now, 13 under way, 2 of them phase 3. trastuzumab deruxtecan · Neoplasm Metastasis.
Among the 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis, this one is the 11th largest by enrollment, is one of 3 that started in 2020, is one of 6 in phase 1, reaches primary completion later than 1 of the 12 other live ones, and was the 7th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →10 of the 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis are open now, in 12 countries. Recruiting first, the newest first:
Gruppo Oncologico del Nord-Ovest · Sites in France, Germany, Italy and 1 more country
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Daiichi Sankyo · Sites in United States, Australia, Brazil and 10 more countries
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
By country, each count listing its studies:
trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab deruxtecan is the treatment under test here. Read study by study →
20 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is above the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 69 across the 20 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
124 studies in Neoplasm Metastasis by National Cancer Institute (NCI): 18 open now, 43 under way, none of them phase 3. Of 73 finished, 29 (40%) have results posted.
Among the 124 studies in Neoplasm Metastasis by National Cancer Institute (NCI), this one is the 29th largest by enrollment of the 112 interventional ones that give a count, is one of 7 that started in 2020, is one of 70 in phase 1, reaches primary completion later than 11 of the 41 other live ones, and was the 94th registered.
National Cancer Institute (NCI)’s Neoplasm Metastasis studies by the year they started, since 1984.
4 of the studies testing trastuzumab deruxtecan in Neoplasm Metastasis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT04585958National Cancer Institute (NCI)Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | 2026-12-31 |
| NCT06058988Memorial Sloan Kettering Cancer CenterTrastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | 2027-09-22 |
| NCT07407465Gruppo Oncologico del Nord-OvestUpfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | 2027-10-20 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis, from their registry updates:
Among National Cancer Institute (NCI)’s 124 in Neoplasm Metastasis:
This tab as a report to print or save as PDF → With an account.
This phase I trial studies the biological effects of trastuzumab deruxtecan (DS-8201a) on patients with human epidermal growth factor receptor 2 (HER2) positive cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). DS-8201a works by binding to a protein called HER2 that is present on the surface of tumor cells. This allows DS-8201a to kill the tumor cells by damaging their deoxyribonucleic acid (DNA), resulting in tumor cell death. This study looks at how DS-8201a may affect the levels of certain proteins and immune cells in tumors and how well the drug works against tumor cells by examining cells from a small piece tumor taken before and after DS-8201a is given.
PRIMARY OBJECTIVE:
I. To assess the effects of trastuzumab deruxtecan (DS-8201a) on total Top1 levels in biopsy specimens from patients with human epidermal growth factor receptor 2 (HER2) -expressing advanced solid tumors, at early and late post-treatment time points, thereby establishing the degree and duration of DS-8201 target engagement.
SECONDARY OBJECTIVES:
I. To assess any associations between serum concentrations of DS-8201a and the effects of DS-8201a on total Top1 levels in tumor biopsy specimens.
II. To determine the safety and tolerability of DS-8201a administered intravenously every 3 weeks, in 21-day cycles, at a dose of 5.4 mg/kg.
III. To determine the overall response rate (complete response [CR] + partial response [PR]) for patients administered intravenously with DS-8201a every 3 weeks, in 21-day cycles, at a dose of 5.4 mg/kg.
EXPLORATORY OBJECTIVES:
I. To evaluate the effects of DS-8201a on cluster of differentiation 8 (CD8+) T cell infiltration and activation in tumor, tumor programmed death-ligand 1 (PD-L1) and HER2 expression, and deoxyribonucleic acid (DNA) damage response (DDR) signaling (for example: gamma H2A histone family member X (H2AX), radiation sensitive 51 (RAD51), and phosphorylated [p]Nibrin (NBS1) in biopsy specimens.
II. To examine genomic alterations in circulating tumor DNA (ctDNA) that may be associated with DS-8201a response or resistance.
III. To examine any associations between baseline tumor HER2 amplification or HER2 expression level and response to DS-8201a.
IV. To evaluate the effects of DS-8201a on tumor levels of HER2 and DDR-associated proteins.
V. To examine any tumor genomic alterations that may be associated with resistance to DS-8201a.
VI. To evaluate anti-drug antibodies following administration of DS-8201a.
OUTLINE:
Patients receive trastuzumab deruxtecan intravenously (IV) over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiography (ECHO) or multi-gated acquisition scan (MUGA), computed tomography (CT) or magnetic resonance imaging (MRI), biopsies, and collection of blood samples throughout the study.
After completion of study treatment, patients are followed up for 40 days.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have human epidermal growth factor receptor 2 ()-positive or HER2-expressing tumors as defined by Clinical Laboratory Improvement Act (CLIA)-certified labs. Patients must have either:
Patients who are (HIV) positive may participate IF they meet the following eligibility requirements:
They must have a cluster of differentiation 4 (CD4) count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a \< 200 cells/uL over the past 2 years, unless it was deemed related to the cancer and/or immunotherapy-induced bone marrow suppression
Exclusion Criteria:
Patients who have had:
Chemotherapy (including antibody drug therapy, retinoid therapy, hormonal therapy for cancer-with the exception of standard of care androgen deprivation treatment) within:
Patients with any of the following pulmonary-related illnesses:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive trastuzumab deruxtecan intravenous (IV) over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiogram (ECHO) or multi-gated acquisition scan (MUGA), computed tomography (CT) or magnetic resonance imaging (MRI), biopsies, and collection of blood samples throughout the study.
Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Echocardiography Test · Procedure: Magnetic Resonance Imaging · Procedure: Multigated Acquisition Scan · Biological: Trastuzumab Deruxtecan
Undergo biopsy
Also known as: Biopsy, BIOPSY_TYPE, Bx
Undergo collection of blood samples
Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection
Undergo computerized tomography (CT) scan
Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography
Undergo echocardiogram (ECHO)
Also known as: EC, Echocardiography, Echocardiogram
Undergo magnetic resonance imaging (MRI)
Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
Undergo multi-gated acquisition scan (MUGA)
Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
Given intravenous (IV)
Also known as: DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516
Change in Total Topoisomerase 1 (TOP1) Levels in Biopsy Specimens at Early and Late Post-Trastuzumab Deruxtecan (DS-8201a) Time Points
Change (i.e., decrease) in total TOP1 protein as measured by the percentage of nuclear area staining positive (%NAP) for TOP1 in biopsies collected after trastuzumab deruxtecan (DS-8201a) treatment compared to baseline biopsies using a quantitative immunofluorescence assay. We do not have any evidence regarding whether an increase or decrease in total TOP1 %NAP after treatment increases the likelihood of the tumor responding to the drug.
Time frame: (Early post treatment compared to baseline) - Up to day 7 of cycle 1 (one cycle = 21 days), for an average of 3.2 days; (late post treatment compared to baseline) Day 1 of cycle 3, for an average of 47 days
Tumor Immune Microenvironment Response After Trastuzumab Deruxtecan (DS-8201a) Treatment
The change in the number of active immune cells in each participants' tumor after treatment with trastuzumab deruxtecan (DS-8201a) compared with baseline, as measured by the number of cells per square millimeter within the tumor that stain positive for both the Cluster of Differentiation 8 (CD8+) protein and the T-cell receptor T3 zeta chain (CD3ζ) protein phosphorylated at Tyrosine 142 (CD3ζ pY142+) using a quantitative immunofluorescence assay. Larger or increasing numbers of active immune cells in the tumor are thought to increase the likelihood of the tumor responding to the drug.
Time frame: Baseline compared to Day 1 of cycle 3 (1 cycle = 21 days), for an average of 47 days
Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Concentration and Change in Total TOP1 Levels in Tumor Biopsies
The association between serum concentrations of trastuzumab deruxtecan (DS-8201a) and the change in total TOP1 levels in tumor biopsies was assessed by computing the sample correlation between the DS-8201a serum concentration at the timepoint closest to the biopsy and the initial change in tumor TOP1 level (from baseline to cycle (C) 1 day (D) 2-4 \[C1D2-4\] biopsy.
Time frame: Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days
Correlation Between Maximum Serum Concentration of Trastuzumab Deruxtecan (DS-8201a) and the Initial Change in TOP1cc in Tumor Biopsies (From Baseline to Cycle 1, 2-4 Days Post-day 1 Dose)
The association between the maximum serum concentration of trastuzumab deruxtecan (DS-8201a) and the initial change in tumor cells' TOP1 covalent complex (TOP1cc) levels will be assessed by computing the sample correlation between the highest DS-8201a serum concentration observed for each participant during cycle 1 of treatment and the initial change in tumor cells with TOP1cc (from baseline to cycle (C) 1 day (D) 2-4 \[C1D2-4\] biopsy
Time frame: Baseline compared to cycle 1 (one cycle = 21 days), 2-4 days post-day 1 dose
Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Area Under the Curve (AUC) Calculation and Change in Total TOP1 Levels in Tumor Biopsies
Area Under the Curve (AUC) is a calculated estimate of the serum concentration of Trastuzumab Deruxtecan (DS-8201a) over time. It is used to characterize the overall exposure over a time interval. The association between participant trastuzumab deruxtecan (DS-8201a) AUC and the change in total TOP1 levels in tumor biopsies was assessed by computing the sample correlation between the DS-8201a AUC and the initial change in tumor TOP1 level (from baseline to cycle (C) 1 day (D) 2-4 \[C1D2-4\] biopsy.
Time frame: Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days
Number of Participants With Grade 2 and Higher Treatment-related Adverse Events, Reporting Only the Worst Grade That is at Least Possibly Related to Study Drugs for Each Participant
Grades 2 and higher adverse events were measured using the Common Terminology Criteria for Adverse Events (CTCAEv5.0). Grade 2 moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.
Time frame: From the start of the treatment until disease progression/recurrence, an average of 6.8 months
Overall Response Rate
The overall response rate (complete response + partial response) among eligible participants who have received at least one dose of trastuzumab deruxtecan (DS-8201a). A 95% confidence interval for this response rate will also be computed. For this analysis, response classifications will follow Response Evaluation Criteria in Solid Tumors version 1.1 guidelines. Complete response is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1cm). Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Overall response rate is the combination of complete and partial responses.
Time frame: From the start of the treatment until disease progression/recurrence, an average of 6.8 months.
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Adverse Events were monitored/assessed from the start of the treatment until disease progression/recurrence, an average of 6.8 months,
| Milestone | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| Started | 62 |
| Started treatment | 61 |
| Completed | 61 |
| Not completed | 1 |
| Withdrew: Did not go on to receive treatment. | 1 |
Change (i.e., decrease) in total TOP1 protein as measured by the percentage of nuclear area staining positive (%NAP) for TOP1 in biopsies collected after trastuzumab deruxtecan (DS-8201a) treatment compared to baseline biopsies using a quantitative immunofluorescence assay. We do not have any evidence regarding whether an increase or decrease in total TOP1 %NAP after treatment increases the likelihood of the tumor responding to the drug.
| %NAP | Changes At Early Post-Treatment (Up to Day 7 of Cycle 1) | Change At Late Post-Treatment (Up to Day 1 of Cycle 3) |
|---|---|---|
| Change in Total Topoisomerase 1 (TOP1) Levels in Biopsy Specimens at Early and Late Post-Trastuzumab Deruxtecan (DS-8201a) Time Points | -4.5 ± 5.9 | -1.3 ± 3.8 |
The change in the number of active immune cells in each participants' tumor after treatment with trastuzumab deruxtecan (DS-8201a) compared with baseline, as measured by the number of cells per square millimeter within the tumor that stain positive for both the Cluster of Differentiation 8 (CD8+) protein and the T-cell receptor T3 zeta chain (CD3ζ) protein phosphorylated at Tyrosine 142 (CD3ζ pY142+) using a quantitative immunofluorescence assay. Larger or increasing numbers of active immune cells in the tumor are thought to increase the likelihood of the tumor responding to the drug.
| cells per millimeter squared(cells/mm^2) | Change At Late Post-Treatment (Up to Day 1 of Cycle 3) |
|---|---|
| Tumor Immune Microenvironment Response After Trastuzumab Deruxtecan (DS-8201a) Treatment | -0.4 ± 12.7 |
The association between serum concentrations of trastuzumab deruxtecan (DS-8201a) and the change in total TOP1 levels in tumor biopsies was assessed by computing the sample correlation between the DS-8201a serum concentration at the timepoint closest to the biopsy and the initial change in tumor TOP1 level (from baseline to cycle (C) 1 day (D) 2-4 \[C1D2-4\] biopsy.
| Correlation Coefficient | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Concentration and Change in Total TOP1 Levels in Tumor Biopsies | 0.24 |
The association between the maximum serum concentration of trastuzumab deruxtecan (DS-8201a) and the initial change in tumor cells' TOP1 covalent complex (TOP1cc) levels will be assessed by computing the sample correlation between the highest DS-8201a serum concentration observed for each participant during cycle 1 of treatment and the initial change in tumor cells with TOP1cc (from baseline to cycle (C) 1 day (D) 2-4 \[C1D2-4\] biopsy
| Correlation Coefficient | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| Correlation Between Maximum Serum Concentration of Trastuzumab Deruxtecan (DS-8201a) and the Initial Change in TOP1cc in Tumor Biopsies (From Baseline to Cycle 1, 2-4 Days Post-day 1 Dose) | 0.17 |
Area Under the Curve (AUC) is a calculated estimate of the serum concentration of Trastuzumab Deruxtecan (DS-8201a) over time. It is used to characterize the overall exposure over a time interval. The association between participant trastuzumab deruxtecan (DS-8201a) AUC and the change in total TOP1 levels in tumor biopsies was assessed by computing the sample correlation between the DS-8201a AUC and the initial change in tumor TOP1 level (from baseline to cycle (C) 1 day (D) 2-4 \[C1D2-4\] biopsy.
| Correlation Coefficient | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Area Under the Curve (AUC) Calculation and Change in Total TOP1 Levels in Tumor Biopsies | NA |
Grades 2 and higher adverse events were measured using the Common Terminology Criteria for Adverse Events (CTCAEv5.0). Grade 2 moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.
| Participants | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| Abdominal pain, grade 2 | 2 |
| Abdominal pain, grade 3 | 1 |
| Activated partial thromboplastin time prolonged, grade 2 | 1 |
| Alanine aminotransferase increased, grade 2 | 1 |
| Alkaline aminotransferase increased, grade 2 | 1 |
| Alopecia, grade 2 | 5 |
| Anemia, grade 2 | 15 |
| Anemia, grade 3 | 14 |
| Anorexia, grade 2 | 8 |
| Anorexia, grade 3 | 2 |
| Anxiety, grade 2 | 1 |
| Ascites, grade 2 | 1 |
| Aspartate aminotransferase increased, grade 2 | 2 |
| Aspartate aminotransferase increased, grade 3 | 1 |
| Blood bilirubin increased, grade 2 | 1 |
| Constipation, grade 2 | 3 |
| Cough, grade 2 | 1 |
| Creatinine increased, grade 2 | 3 |
| Dehydration, grade 2 | 2 |
| Dehydration, grade 3 | 1 |
| Diarrhea, grade 2 | 9 |
| Diarrhea, grade 3 | 3 |
| Dysgeusia, grade 2 | 1 |
| Dyspepsia, grade 2 | 2 |
| Dyspnea, grade 2 | 2 |
| Dyspnea, grade 3 | 1 |
| Edema limbs, grade 2 | 1 |
| Ejection fraction decreased, grade 2 | 1 |
| Fall, grade 3 | 1 |
| Fatigue, grade 2 | 18 |
| Fatigue, grade 3 | 5 |
| Fever, grade 2 | 2 |
| Flu like symptoms, grade 2 | 1 |
| Gastroesophageal reflux disease, grade 2 | 1 |
| Generalized muscle weakness, grade 2 | 4 |
| Generalized muscle weakness, grade 3 | 1 |
| Hepatobiliary disorders - Other Liver fibrosis, grade 2 | 1 |
| Hiccups, grade 2 | 1 |
| Hypertension, grade 3 | 1 |
| Hypokalemia, grade 2 | 1 |
| Hypokalemia, grade 3 | 2 |
| Hypomagnesemia, grade 2 | 1 |
| Hyponatremia, grade 2 | 3 |
| Hyponatremia, grade 3 | 1 |
| Hypophosphatemia, grade 2 | 1 |
| Hypotension, grade 2 | 1 |
| Hypoxia, grade 2 | 1 |
| Hypoxia, grade 3 | 1 |
| Lymphocyte count decreased, grade 2 | 8 |
| Lymphocyte count decreased, grade 3 | 6 |
| Lymphocyte count decreased, grade 4 | 1 |
| Mucositis grade 2 | 3 |
| Nausea, grade 2 | 22 |
| Nausea, grade 3 | 1 |
| Neutrophil count decreased, grade 2 | 7 |
| Neutrophil count decreased, grade 3 | 3 |
| Neutrophil count decreased, grade 4 | 2 |
| Platelet count decreased, grade 2 | 2 |
| Platelet count decreased, grade 3 | 1 |
| Platelet count decreased, grade 4 | 1 |
| Pleural effusion, grade 2 | 1 |
| Pneumonitis, grade 2 | 9 |
| Pneumonitis, grade 3 | 1 |
| Presyncope, grade 2 | 1 |
| Rash maculo-papular, grade 2 | 2 |
| Skin infection, grade 2 | 1 |
| Syncope, grade 3 | 1 |
| Thrush, grade 2 | 1 |
| Urinary tract infection, grade 2 | 2 |
| Vomiting, grade 2 | 7 |
| Weight loss, grade 2 | 5 |
| White blood cell decreased, grade 2 | 17 |
| White blood cell decreased, grade 3 | 2 |
| Grade 5 Treatment Related Adverse Events | 0 |
The overall response rate (complete response + partial response) among eligible participants who have received at least one dose of trastuzumab deruxtecan (DS-8201a). A 95% confidence interval for this response rate will also be computed. For this analysis, response classifications will follow Response Evaluation Criteria in Solid Tumors version 1.1 guidelines. Complete response is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1cm). Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Overall response rate is the combination of complete and partial responses.
| Percentage of participants | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| Overall Response Rate | 24.6 (14.5 to 37.3) |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
| Participants | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 61 |
Collected over All-Cause Mortality was monitored/assessed an average of 4.9 months. Adverse Events were monitored/assessed from the start of the treatment until disease progression/recurrence, an average of 6.8 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles | 5/62 (8.1%) | 37/61 (60.7%) | 61/61 (100%) |
| Event | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| AnemiaBlood and lymphatic system disorders | 9/61 |
| FatigueGeneral disorders | 7/61 |
| DiarrheaGastrointestinal disorders | 5/61 |
| NauseaGastrointestinal disorders | 5/61 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 4/61 |
| Urinary tract infectionInfections and infestations | 4/61 |
| VomitingGastrointestinal disorders | 4/61 |
| FeverGeneral disorders | 3/61 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 3/61 |
| Neutrophil count decreasedInvestigations | 3/61 |
| Event | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| NauseaGastrointestinal disorders | 53/61 |
| AnemiaBlood and lymphatic system disorders | 46/61 |
| FatigueGeneral disorders | 41/61 |
| HypoalbuminemiaMetabolism and nutrition disorders | 35/61 |
| HyperglycemiaMetabolism and nutrition disorders | 34/61 |
| HyponatremiaMetabolism and nutrition disorders | 33/61 |
| Alkaline phosphatase increasedInvestigations | 31/61 |
| AnorexiaMetabolism and nutrition disorders | 31/61 |
| DiarrheaGastrointestinal disorders | 31/61 |
| VomitingGastrointestinal disorders | 31/61 |
Baseline characteristics data collected for all enrolled participants (N=62), including those enrolled and consented but not treated (n=1) are included here.
| Age, Categorical(Participants) | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 31 |
| >=65 years | 31 |
| Age, Continuous(years) | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| Mean | 65.5 ± 12.2 |
| Sex: Female, Male(Participants) | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| Female | 49 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 57 |
| Unknown or Not Reported | 3 |
| Race (NIH/OMB)(Participants) | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 12 |
| White | 46 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Trastuzumab Deruxtecan (DS-8201a) 5.4 mg/kg Every 3 Weeks in 21-Day Cycles |
|---|---|
| United States | 62 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — National Cancer Institute (NCI) is committed to sharing data in accordance with National Institutes of Health (NIH) policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: At the time of publication or shortly thereafter.
Access criteria: Data will be shared through a National Institutes of Health (NIH) funded or approved public repository: clinicaltrials.gov and Biomedical Translational Research Information System (BTRIS). Approved outside collaborators under appropriate individual agreements. Publication and/or public presentations.
Data sharing details ↗ · grants.nih.gov
Ran from Sep 2020 to primary completion in Sep 2025, 60 months.
Results were first posted in Nov 2026, 1 year 2 months after primary completion.
Of 209 non-industry phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's 60 months is close to that.
Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan
National Cancer Institute (NCI) →